Skip to main contentSkip to navigationSkip to search
Curasight

Curasight presents at HC Andersen Capital

August 23, 2021

Regulatory

Curasight A/S (“Curasight” or the “Company”) CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the Interim Report First Half 2021 at HC Andersen Capital, 24 August 2021.

The presentation will be webcasted live 13:30 - 14:00 (CET), Tuesday 24 August 2021.

For more information please click here

 

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.